On June 11, 2023, Qingdao Baheal Medical Co., Ltd. (also known as "Baheal Medical," 301015.SZ) entered into a strategic partnership agreement with Zhongshan RabPharma Pharmaceutical Co., Ltd. (known as "RabPharma"). Baheal Medical and RabPharma have embarked on a strategic collaboration focused on the commercialization of RAB001 injection (known as "RAB001"), a first-in-class innovative drug for osteonecrosis, within mainland China.

Osteonecrosis, also known as ischemic necrosis or aseptic necrosis, involves a series of complex pathological processes wherein active bone components die due to disrupted blood circulation. This disruption can be caused by various factors such as mechanical, biological, and others. It is estimated that there are over 10 million cases of osteonecrosis in China, with an annual increase of 200,000 cases. Despite the prevalence, no specific drugs have been approved globally for osteonecrosis treatment. Surgical interventions often cause significant trauma, have considerable side effects, and entail challenging recovery, creating a substantial clinical demand for osteonecrosis treatment drugs.

RabPharma, an innovative drug R&D company specializing in challenging orthopedic diseases, is backed by Baheal Medical's parent company, Baheal Pharma Group Co., Ltd. (also known as "Baheal Medical Group"). The company focuses on meeting unmet clinical drug needs both in China and globally by researching and developing first-in-class innovative orthopedic medications. RAB001, RabPharma's pioneering drug for osteonecrosis treatment, is a peptide-linked drug (PDC) capable of homing, migrating, and differentiating into bone-forming mesenchymal stem cells (MSCs). Phase I clinical trials have been completed in the United States, and the Chinese Phase I trials are anticipated to conclude in August. RAB001 is expected to address the gap in targeted treatments for osteonecrosis and osteoporosis.

At the signing ceremony, RabPharma Chairman Chen Jiwei stated: "Since its inception, RabPharma has concentrated on the research and development of innovative drugs for bone and joint disorders. Our first pioneering product, RAB001, has entered clinical trials. Baheal Medical is a highly-regarded third-party commercialization platform in the industry, possessing expertise in brand commercialization. Through this collaboration, we hope both parties will complement each other and jointly advance the research and development of RabPharma's innovative drug-related projects, addressing unmet clinical needs and benefiting patients."

Baheal Medical Vice President Wang Tingwei remarked: "As a third-party commercialization platform specializing in brand operations, Baheal Medical is dedicated to introducing products that genuinely enhance medical situations and improve clinical treatment plans. RabPharma's RAB001 is a groundbreaking drug for non-traumatic osteonecrosis, and holds significant importance for treating this condition. Baheal Medical will offer commercialization support services for RabPharma's RAB001, assisting the innovative product in rapidly realizing its value."

As a top-tier third-party health brand commercialization platform in the A-share market, Baheal Medical has consistently focused on commercializing high-quality medical and healthcare products. By constructing a "brand highways" and offering comprehensive commercialization solutions for upstream industry enterprises, it has forged partnerships with well-known multinational pharmaceutical companies such as Roche, AstraZeneca, and Astellas. Baheal Medical's brand categories encompasses OTC and healthcare, OTX and prescription drug, oncology drugs, as well as high-end medical devices. Utilizing their professional brand operation capabilities, Baheal Medical will persist in expanding their product range and actively take on original innovative drugs that can enhance medical scenarios, thereby fueling the company's ongoing sustainable development.